FDA says no to Novartis heart drug

Share this article:
Novartis announces good heart drug results
Novartis announces good heart drug results

The FDA hit drugmaker Novartis with a setback Friday, rejecting the company's experimental acute heart-failure drug serelaxin through a Complete Response Letter.

Novartis announced the CRL Friday, saying the US regulator wanted more efficacy information than the Phase-II and Phase-III safety and efficacy data that accompanied the filing.

Although the FDA does not have to adhere to advisory panel recommendations, Friday's news synchs with an FDA panel's March vote against the drug, which rang in at 11-0.

Novartis is not giving up on the drug, despite Friday's announcement and the European Medicines
Agency's rejection in January. Instead, the company said it will expand the data set with a patient pool that will ultimately include 6,300 patients worldwide.

Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.